Diana Stempak

1.3k total citations
22 papers, 975 citations indexed

About

Diana Stempak is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Diana Stempak has authored 22 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Oncology. Recurrent topics in Diana Stempak's work include Angiogenesis and VEGF in Cancer (6 papers), Inflammatory mediators and NSAID effects (6 papers) and Glioma Diagnosis and Treatment (4 papers). Diana Stempak is often cited by papers focused on Angiogenesis and VEGF in Cancer (6 papers), Inflammatory mediators and NSAID effects (6 papers) and Glioma Diagnosis and Treatment (4 papers). Diana Stempak collaborates with scholars based in Canada, United States and Italy. Diana Stempak's co-authors include Sylvain Baruchel, Gideon Koren, Janet Gammon, Julia Glade Bender, Julia Klein, Susan M. Blaney, Peter C. Adamson, Ashish M. Ingle, Albert Moghrabi and Yuval Shaked and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PEDIATRICS.

In The Last Decade

Diana Stempak

22 papers receiving 960 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Stempak Canada	16	380	269	254	202	178	22	975
Lisa Iacono United States	14	320 0.8×	223 0.8×	278 1.1×	200 1.0×	211 1.2×	34	761
ES Newlands United Kingdom	16	336 0.9×	118 0.4×	258 1.0×	120 0.6×	172 1.0×	38	1.0k
Christopher S. Hong United States	19	514 1.4×	195 0.7×	191 0.8×	240 1.2×	348 2.0×	89	1.3k
Claudio Zanna Switzerland	19	411 1.1×	158 0.6×	862 3.4×	166 0.8×	114 0.6×	49	1.4k
James Raschko United States	20	212 0.6×	83 0.3×	416 1.6×	179 0.9×	88 0.5×	50	1.1k
Jae‐Yong Kwak South Korea	21	233 0.6×	134 0.5×	398 1.6×	103 0.5×	263 1.5×	115	1.3k
Ilaria Ruffilli Italy	27	469 1.2×	79 0.3×	528 2.1×	237 1.2×	61 0.3×	54	2.2k
Jihao Zhou United States	17	391 1.0×	163 0.6×	220 0.9×	175 0.9×	58 0.3×	61	1.7k
F. Javier Carmona Spain	18	1.1k 2.9×	84 0.3×	262 1.0×	151 0.7×	57 0.3×	25	1.6k
Xiaogang Li China	19	499 1.3×	101 0.4×	242 1.0×	117 0.6×	131 0.7×	73	1.2k

Countries citing papers authored by Diana Stempak

Since Specialization

Citations

This map shows the geographic impact of Diana Stempak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Stempak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Stempak more than expected).

Fields of papers citing papers by Diana Stempak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Stempak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Stempak. The network helps show where Diana Stempak may publish in the future.

Co-authorship network of co-authors of Diana Stempak

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Stempak. A scholar is included among the top collaborators of Diana Stempak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Stempak. Diana Stempak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Widemann, Brigitte C., AeRang Kim, Elizabeth Fox, et al.. (2012). A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research. 18(21). 6011–6022. 90 indexed citations

DuBois, Steven G., Diana Stempak, Bing Wu, et al.. (2011). Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatric Blood & Cancer. 58(2). 181–184. 12 indexed citations

Baruchel, Sylvain, Bing Wu, Reza Bayat Mokhtari, et al.. (2011). Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials.. Journal of Clinical Oncology. 29(15_suppl). 9502–9502. 8 indexed citations

Bouffet, Éric, Diana Stempak, Janet Gammon, et al.. (2010). A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. European Journal of Cancer. 46(18). 3271–3279. 34 indexed citations

Baruchel, Sylvain, Ute Bartels, Juliette Hukin, et al.. (2009). A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. European Journal of Cancer. 45(13). 2352–2359. 23 indexed citations

Zhang, Libo, Kristen M. Smith, Amy Lee Chong, et al.. (2009). In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model. Neoplasia. 11(5). 426–435. 61 indexed citations

Shusterman, Suzanne, Sylvain Baruchel, Diana Stempak, et al.. (2008). A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: A Children’s Oncology Group Phase I Consortium study. Journal of Clinical Oncology. 26(15_suppl). 3561–3561. 3 indexed citations

Bender, Julia Glade, Peter C. Adamson, Joel M. Reid, et al.. (2008). Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology. 26(3). 399–405. 202 indexed citations

Seely, Dugald, Diana Stempak, & Sylvain Baruchel. (2007). A Strategy for Controlling Potential Interactions Between Natural Health Products and Chemotherapy. Journal of Pediatric Hematology/Oncology. 29(1). 32–47. 19 indexed citations

10.

Pope, Elena, Bernice R. Krafchik, Colin Macarthur, et al.. (2007). Oral Versus High-Dose Pulse Corticosteroids for Problematic Infantile Hemangiomas: A Randomized, Controlled Trial. PEDIATRICS. 119(6). e1239–e1247. 78 indexed citations

11.

Baruchel, Sylvain, Manuel Diezi, Darren Hargrave, et al.. (2006). Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours. European Journal of Cancer. 42(14). 2335–2342. 69 indexed citations

12.

Stempak, Diana, Dugald Seely, & Sylvain Baruchel. (2006). Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology. Cancer Investigation. 24(4). 432–443. 23 indexed citations

13.

Lee, Alice, Jason S. Frischer, Anna Serur, et al.. (2006). Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling. Cancer Research. 66(8). 4378–4384. 29 indexed citations

14.

Stempak, Diana, Janet Gammon, Jacqueline Halton, et al.. (2006). A Pilot Pharmacokinetic and Antiangiogenic Biomarker Study of Celecoxib and Low-dose Metronomic Vinblastine or Cyclophosphamide in Pediatric Recurrent Solid Tumors. Journal of Pediatric Hematology/Oncology. 28(11). 720–728. 66 indexed citations

15.

Buckstein, Rena, Robert S. Kerbel, Yuval Shaked, et al.. (2006). High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma. Clinical Cancer Research. 12(17). 5190–5198. 81 indexed citations

16.

Klement, Giannoula, et al.. (2005). Targeting Cyclooxygenase-2 Reduces Overt Toxicity toward Low-Dose Vinblastine and Extends Survival of Juvenile Mice with Friend Disease. Clinical Cancer Research. 11(2). 712–719. 12 indexed citations

17.

Buckstein, Rena, Michael Crump, Yuval Shaked, et al.. (2004). High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL.. Blood. 104(11). 4622–4622. 1 indexed citations

18.

Knoppert, David, Diana Stempak, Sylvain Baruchel, & Gideon Koren. (2003). Celecoxib in Human Milk: A Case Report. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 23(1). 97–100. 18 indexed citations

19.

Fouladi, Maryam, Diana Stempak, Janet Gammon, et al.. (2001). Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer. 92(4). 914–923. 23 indexed citations

20.

Stempak, Diana, Shannon Dallas, Julia Klein, et al.. (2001). Glutathione Stability in Whole Blood: Effects of Various Deproteinizing Acids. Therapeutic Drug Monitoring. 23(5). 542–549. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact